Latest Insider Transactions at Athira Pharma, Inc. (ATHA)
This section provides a real-time view of insider transactions for Athira Pharma, Inc. (ATHA). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Athira Pharma, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Athira Pharma, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 05
2024
|
Rachel Lenington COO and CDO |
SELL
Open market or private sale
|
Direct |
2,525
-10.79%
|
$0
$0.57 P/Share
|
|
Sep 05
2024
|
Andrew Gengos CFO and Chief Business Officer |
SELL
Open market or private sale
|
Direct |
1,272
-1.29%
|
$0
$0.57 P/Share
|
|
Sep 05
2024
|
Mark James Litton President and CEO |
SELL
Open market or private sale
|
Direct |
5,032
-3.06%
|
$0
$0.57 P/Share
|
|
Sep 05
2024
|
Mark Worthington General Counsel and CCO |
SELL
Open market or private sale
|
Direct |
2,525
-4.64%
|
$0
$0.57 P/Share
|
|
Sep 05
2024
|
Kevin Church CHIEF SCIENTIFIC OFFICER |
SELL
Open market or private sale
|
Direct |
2,525
-2.65%
|
$0
$0.57 P/Share
|
|
Sep 03
2024
|
Rachel Lenington COO and CDO |
BUY
Grant, award, or other acquisition
|
Direct |
10,000
+29.94%
|
-
|
|
Sep 03
2024
|
Andrew Gengos CFO and Chief Business Officer |
BUY
Grant, award, or other acquisition
|
Direct |
5,000
+4.82%
|
-
|
|
Sep 03
2024
|
Mark James Litton President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
20,000
+10.85%
|
-
|
|
Sep 03
2024
|
Mark Worthington General Counsel and CCO |
BUY
Grant, award, or other acquisition
|
Direct |
10,000
+15.52%
|
-
|
|
Sep 03
2024
|
Kevin Church CHIEF SCIENTIFIC OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
10,000
+9.5%
|
-
|
|
Jun 24
2024
|
Kelly A Romano |
BUY
Open market or private purchase
|
Direct |
27,400
+25.34%
|
$54,800
$2.42 P/Share
|
|
Jun 21
2024
|
Kelly A Romano |
BUY
Open market or private purchase
|
Direct |
15,000
+21.96%
|
$30,000
$2.26 P/Share
|
|
May 20
2024
|
Andrew Gengos CFO and Chief Business Officer |
BUY
Grant, award, or other acquisition
|
Direct |
10,000
+9.63%
|
$10,000
$1.34 P/Share
|
|
May 20
2024
|
Mark Worthington General Counsel and CCO |
BUY
Grant, award, or other acquisition
|
Direct |
10,000
+18.36%
|
$10,000
$1.34 P/Share
|
|
May 20
2024
|
Kevin Church CHIEF SCIENTIFIC OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
4,953
+5.49%
|
$4,953
$1.34 P/Share
|
|
Jan 05
2024
|
Mark James Litton President and CEO |
SELL
Open market or private sale
|
Direct |
4,820
-3.23%
|
$9,640
$2.91 P/Share
|
|
Jan 05
2024
|
Rachel Lenington COO and CDO |
SELL
Open market or private sale
|
Direct |
2,412
-15.26%
|
$4,824
$2.91 P/Share
|
|
Jan 05
2024
|
Mark Worthington General Counsel and CCO |
SELL
Open market or private sale
|
Direct |
2,412
-6.54%
|
$4,824
$2.91 P/Share
|
|
Jan 04
2024
|
Hans Moebius Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
10,000
+9.85%
|
-
|
|
Jan 04
2024
|
Mark James Litton President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
20,000
+11.82%
|
-
|
|
Jan 04
2024
|
Rachel Lenington COO and CDO |
BUY
Grant, award, or other acquisition
|
Direct |
10,000
+38.75%
|
-
|
|
Jan 04
2024
|
Mark Worthington General Counsel and CCO |
BUY
Grant, award, or other acquisition
|
Direct |
10,000
+21.34%
|
-
|
|
Dec 29
2023
|
Perceptive Advisors LLC Director |
BUY
Open market or private purchase
|
Indirect |
163,954
+2.95%
|
$327,908
$2.38 P/Share
|
|
Dec 28
2023
|
Perceptive Advisors LLC Director |
BUY
Open market or private purchase
|
Indirect |
409,598
+7.25%
|
$819,196
$2.44 P/Share
|
|
Dec 27
2023
|
Perceptive Advisors LLC Director |
BUY
Open market or private purchase
|
Indirect |
32,134
+0.66%
|
$64,268
$2.28 P/Share
|
|
Nov 20
2023
|
Kevin Church CHIEF SCIENTIFIC OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
3,397
+4.47%
|
$3,397
$1.34 P/Share
|
|
Jun 07
2023
|
Andrew Gengos CFO and Chief Business Officer |
BUY
Open market or private purchase
|
Direct |
15,000
+5.81%
|
$45,000
$3.4 P/Share
|
|
Jun 05
2023
|
Andrew Gengos CFO and Chief Business Officer |
BUY
Open market or private purchase
|
Direct |
45,000
+19.22%
|
$135,000
$3.01 P/Share
|
|
Jun 02
2023
|
Hans Moebius Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,882
+8.82%
|
$7,882
$1.35 P/Share
|
|
Jun 02
2023
|
Andrew Gengos CFO and Chief Business Officer |
BUY
Open market or private purchase
|
Direct |
20,012
+31.0%
|
$40,024
$2.85 P/Share
|
|
May 18
2023
|
Kevin Church CHIEF SCIENTIFIC OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
809
+1.15%
|
$1,618
$2.41 P/Share
|
|
May 18
2023
|
Mark Worthington General Counsel and CCO |
BUY
Grant, award, or other acquisition
|
Direct |
7,767
+22.43%
|
$15,534
$2.41 P/Share
|
|
May 18
2023
|
Hans Moebius Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
7,764
+9.54%
|
$15,528
$2.41 P/Share
|
|
Mar 30
2023
|
Grant Pickering |
BUY
Open market or private purchase
|
Direct |
15,000
+36.78%
|
$30,000
$2.47 P/Share
|
|
Mar 29
2023
|
Grant Pickering |
BUY
Open market or private purchase
|
Direct |
10,000
+48.12%
|
$20,000
$2.33 P/Share
|
|
Mar 29
2023
|
James A Johnson |
BUY
Open market or private purchase
|
Direct |
5,000
+50.0%
|
$10,000
$2.4 P/Share
|
|
Mar 24
2023
|
Kevin Church CHIEF SCIENTIFIC OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
6,410
+8.56%
|
$6,410
$1.35 P/Share
|
|
Jan 05
2023
|
Andrew Gengos CFO and Chief Business Officer |
SELL
Open market or private sale
|
Direct |
1,208
-1.42%
|
$2,416
$2.91 P/Share
|
|
Jan 05
2023
|
Kevin Church CHIEF SCIENTIFIC OFFICER |
SELL
Open market or private sale
|
Direct |
2,412
-2.92%
|
$4,824
$2.91 P/Share
|
|
Jan 04
2023
|
Andrew Gengos CFO and Chief Business Officer |
BUY
Grant, award, or other acquisition
|
Direct |
5,000
+5.55%
|
-
|
|
Jan 04
2023
|
Kevin Church CHIEF SCIENTIFIC OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
10,000
+10.79%
|
-
|
|
Dec 28
2022
|
Glenna Mileson Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
50,000
+23.82%
|
$100,000
$2.85 P/Share
|
|
Dec 02
2022
|
Kelly A Romano |
BUY
Open market or private purchase
|
Direct |
30,000
+43.91%
|
$90,000
$3.29 P/Share
|
|
Nov 18
2022
|
Mark James Litton President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
662
+0.51%
|
$1,324
$2.74 P/Share
|
|
Nov 18
2022
|
Kevin Church CHIEF SCIENTIFIC OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
657
+1.05%
|
$1,314
$2.74 P/Share
|
|
Nov 18
2022
|
Glenna Mileson Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
763
+0.69%
|
$1,526
$2.74 P/Share
|
|
Nov 15
2022
|
Hans Moebius Chief Medical Officer |
BUY
Open market or private purchase
|
Direct |
5,000
+7.06%
|
$15,000
$3.29 P/Share
|
|
Oct 28
2022
|
Kevin Church CHIEF SCIENTIFIC OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
3,700
+5.68%
|
$3,700
$1.35 P/Share
|
|
Oct 13
2022
|
Hans Moebius Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,881
+11.47%
|
$7,881
$1.35 P/Share
|
|
Jun 30
2022
|
Perceptive Advisors LLC Director |
BUY
Open market or private purchase
|
Indirect |
1,101,362
+18.67%
|
$2,202,724
$2.99 P/Share
|